Citadel Advisors’s Coherus Oncology CHRS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$204K Buy
121,000
+100,000
+476% +$178K ﹤0.01% 11371
2025
Q4
$29.8K Sell
21,000
-98,700
-82% -$144K ﹤0.01% 12226
2025
Q3
$196K Buy
119,700
+88,700
+286% +$98.7K ﹤0.01% 11285
2025
Q2
$22.7K Sell
31,000
-34,300
-53% -$29.6K ﹤0.01% 12077
2025
Q1
$52.7K Sell
65,300
-26,500
-29% -$30.5K ﹤0.01% 12262
2024
Q4
$127K Buy
91,800
+52,300
+132% +$58.7K ﹤0.01% 11111
2024
Q3
$41.1K Sell
39,500
-11,400
-22% -$15.6K ﹤0.01% 12122
2024
Q2
$88.1K Sell
50,900
-34,700
-41% -$69.8K ﹤0.01% 11095
2024
Q1
$205K Sell
85,600
-38,384
-31% -$94.5K ﹤0.01% 10279
2023
Q4
$413K Buy
123,984
+69,684
+128% +$187K ﹤0.01% 8502
2023
Q3
$203K Buy
54,300
+14,100
+35% +$65.1K ﹤0.01% 9883
2023
Q2
$172K Buy
40,200
+32,600
+429% +$192K ﹤0.01% 10119
2023
Q1
$52K Sell
7,600
-31,400
-81% -$244K ﹤0.01% 12097
2022
Q4
$309K Buy
+39,000
New +$300K ﹤0.01% 9254
2021
Q4
Sell
-14,100
Closed -$227K 13860
2021
Q3
$227K Sell
14,100
-11,200
-44% -$164K ﹤0.01% 11700
2021
Q2
$350K Buy
25,300
+400
+2% +$5.67K ﹤0.01% 10890
2021
Q1
$364K Buy
24,900
+9,800
+65% +$166K ﹤0.01% 10394
2020
Q4
$262K Buy
+15,100
New +$269K ﹤0.01% 9298
2020
Q2
Sell
-10,300
Closed -$167K 9834
2020
Q1
$167K Sell
10,300
-5,300
-34% -$97.9K ﹤0.01% 8185
2019
Q4
$281K Buy
15,600
+5,600
+56% +$103K ﹤0.01% 7680
2019
Q3
$203K Sell
10,000
-1,900
-16% -$38K ﹤0.01% 8134
2019
Q2
$263K Buy
+11,900
New +$207K ﹤0.01% 7783
2019
Q1
Sell
-17,100
Closed -$155K 9300
2018
Q4
$155K Sell
17,100
-2,700
-14% -$31.2K ﹤0.01% 8035
2018
Q3
$327K Buy
+19,800
New +$351K ﹤0.01% 7428
2017
Q3
Sell
-11,500
Closed -$165K 7568
2017
Q2
$165K Buy
+11,500
New +$221K ﹤0.01% 6674

Other funds holding CHRS